Immunotherapy of Diseases and Nanotechnology: Current State and Prospects-Reference-Cited by-同舟云学术

Immunotherapy of Diseases and Nanotechnology: Current State and Prospects

Published:2024-06-19 Issue:1 Volume:22 Page:13-21
ISSN:2518-1548
Container-title:Journal of Organic and Pharmaceutical Chemistry
language:
Short-container-title:J. Org. Pharm. Chem.

Author:

Piminov Oleksandr F.¹^ORCID,Sahaidak-Nikitiuk Rita V.¹^ORCID,Kvitchata Anna I.¹^ORCID,Rolik-Attia Svitlana M.¹^ORCID

Affiliation:

1. Institute for Advanced Training of Pharmacy Specialists of the National University of Pharmacy of the Ministry of Health of Ukraine

Abstract

Nanotechnology can be used to treat a number of diseases, which are currently the main cause of death in the world, and allow to achieve the desired therapeutic effect for the patient. This mini-review focuses on the analysis of scientific literary sources dealing with the application of nanotechnology in the immunotherapy of diseases and covers the period from 2016 to 2022. In particular, it provides an overview of recently discovered nanotechnologies (including immunomodulatory nanosystems) used for the prevention and treatment of various diseases, including cancer, infectious, inflammatory, and autoimmune diseases. The review also discusses the role of nanosystems in cancer immunotherapy. Additional attention is paid to nanomaterials with new structures, properties, and functions, which are used in the modern practice of treating viral and bacterial infections. A part of the paper is devoted to nanoparticles that enhance the effect of immunosuppressive cells in the treatment of inflammatory and autoimmune diseases. The analysis performed clearly demonstrates the relevance of nanotechnologies for the use in the immunotherapy of diseases. We hope it will allow researchers to identify new areas for using nanoparticles in the treatment of diseases of various etiologies.

Publisher

National University of Pharmacy

Reference64 articles.

1. Pearson, R. M.; Casey, L. M.; Hughes, K. R.; Miller, S. D.; Shea, L. D. In vivo reprogramming of immune cells: Technologies for induction of antigen-specific tolerance. Adv. Drug Deliv. Rev. 2017, 114, 240-255. https://doi.org/10.1016/j.addr.2017.04.005.

2. Tazaki, T.; Tabata, K.; Ainai, A.; Ohara, Y.; Kobayashi, S.; Ninomiya, T.; Orba, Y.; Mitomo, H.; Nakano, T.; Hasegawa, H.; Ijiro, K.; Sawa, H.; Suzuki, T.; Niikura, K. Shape-dependent adjuvanticity of nanoparticle-conjugated RNA adjuvants for intranasal inactivated influenza vaccines. RSC Adv. 2018, 8 (30), 16527-16536. https://doi.org/1039/C8RA01690A.

3. Kim, H.; Niu L.; Larson, P.; Kucaba, T. A.; Murphy, K. A.; James, B. R.; Ferguson, D. M.; Griffith, T. S.; Panyam, J. Polymeric nanoparticles encapsulating novel TLR7/8 agonists as immunostimulatory adjuvants for enhanced cancer immunotherapy. Biomaterials 2018, 164, 38-53. https://doi.org/10.1016/j.biomaterials.2018.02.034.

4. Chen, J.; Ding, J.; Xu, W.; Sun, T.; Xiao, H.; Zhuang, X.; Chen, X. Receptor and Microenvironment Dual-Recognizable Nanogel for Targeted Chemotherapy of Highly Metastatic Malignancy. Nano Lett. 2017, 17 (7), 4526– https://doi.org/10.1021/acs.nanolett.7b02129.

5. Xu, W.; Ding, J.; Chen, X. Reduction-Responsive Polypeptide Micelles for Intracellular Delivery of Antineoplastic Agent. Biomacromolecules 2017, 18 (10), 3291– https://doi.org/10.1021/acs.biomac.7b00950.